Last reviewed 2026-05-22 · How we verify

Bykonox (VINYLBITAL)

Phase 2 active Small molecule ✓ Verified May 2026

Bykonox (generic name: VINYLBITAL) is a vinylbital drug. It is currently in Phase 2 development.

Bykonox works by interacting with the central nervous system to produce a sedative effect.

Bykonox is a small molecule with the synonyms BUTYLVINAL, JD-96, JD96, OPTANOX, SPEDA, and VINILBITAL.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VINYLBITAL
Drug class	vinylbital
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a busy city with many thoughts and activities happening at the same time. Bykonox helps calm down the city by reducing the activity of certain brain cells, leading to a sense of relaxation and reduced anxiety.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bykonox CI brief — competitive landscape report
Bykonox updates RSS · CI watch RSS

Frequently asked questions about Bykonox

What is Bykonox?

Bykonox (VINYLBITAL) is a vinylbital drug.

How does Bykonox work?

Bykonox works by interacting with the central nervous system to produce a sedative effect.

What is the generic name of Bykonox?

VINYLBITAL is the generic (nonproprietary) name of Bykonox.

What drug class is Bykonox in?

Bykonox belongs to the vinylbital class. See all vinylbital drugs at /class/vinylbital.

What development phase is Bykonox in?

Bykonox is in Phase 2.

Drug class: All vinylbital drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing